Piper Sandler analyst Matthew O’Brien reiterated a Buy rating on Minerva Surgical (UTRS – Research Report) today and set a price target of $3.00. The company’s shares closed yesterday at $2.13.
O’Brien covers the Healthcare sector, focusing on stocks such as Stryker, Sight Sciences, and Alphatec Holdings. According to TipRanks, O’Brien has an average return of 2.0% and a 46.39% success rate on recommended stocks.
Minerva Surgical has an analyst consensus of Moderate Buy, with a price target consensus of $3.00.
See today’s best-performing stocks on TipRanks >>
UTRS market cap is currently $21.49M and has a P/E ratio of -0.14.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Minerva Surgical (UTRS) Company Description:
Minerva Surgical Inc is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women.
Read More on UTRS:
